The life sciences industry is currently undergoing a significant transformation, driven by the rapid development of new modalities such as cell and gene therapies (CAGT), and substantial ne
There has been significant evolution in the European regulatory landscape over the past 10 years, particularly in terms of requirements for clinical evaluation, driven in part by
